Recovery · Reference
BPC-157 Benefits: What the Research Actually Shows
This page goes benefit by benefit. For each claim you will see what was actually studied, in what (rats, cells or people), and how much weight it can bear. It then covers side effects, where BPC-157 stands with the FDA, and how Pepti supplies it. For the full reference on the molecule itself, see what is BPC-157.
Medically reviewed by Dr. Gene, MD · November 4, 2026
Treatments mentioned
The benefits described for BPC-157 come almost entirely from animal and cell research: faster tendon and ligament repair in rats, protection of the stomach and intestinal lining against NSAIDs and alcohol in rodents, and new blood vessel growth into injured tissue. In people, the evidence is thin: one randomized trial of a BPC-157 enema in ulcerative colitis that was only ever published as a 2005 conference abstract, plus a handful of small uncontrolled pilots. There is no randomized human trial of injectable BPC-157 for any use. That makes every benefit below something research describes, not something a vial can promise.
This page goes benefit by benefit. For each claim you will see what was actually studied, in what (rats, cells or people), and how much weight it can bear. It then covers side effects, where BPC-157 stands with the FDA, and how Pepti supplies it. For the full reference on the molecule itself, see what is BPC-157.
BPC-157 Benefits
The short answer
| Claimed benefit | What the evidence is | Strength of evidence |
|---|---|---|
| Tendon and ligament repair | Animal (rat Achilles tendon and knee ligament studies) and cell (cultured tendon fibroblasts) | Consistent in rats; no human trial |
| Protecting the stomach lining from NSAIDs and alcohol | Animal (decades of rodent work) | The largest animal literature; no human trial |
| Inflammatory bowel conditions | Animal (rat colitis models); human (one 2005 enema trial, abstract only) | Weak in humans; the one trial was inconclusive |
| Fistula and bowel surgery repair | Animal (rat fistula and anastomosis studies) | Animal only |
| Gut permeability ("leaky gut") | Cell and animal (one 2020 paper) | Preliminary |
| Muscle injury recovery | Animal (crush and myotendinous junction models) | Animal only |
| New blood vessel growth into injured tissue | Animal and cell (VEGFR2 pathway work) | Mechanism well described in animals; not measured in people |
| Knee and joint pain | Human (one 17-person retrospective chart review) | Very weak; uncontrolled |
| Liver protection | Animal (rat chemical-injury models) | Animal only, with a mixed signal |
| Raising growth hormone | Cell (receptor expression only) | Not supported; it does not raise growth hormone |
| Mood and the brain-gut axis | Review of animal work | Speculative and often overstated |
The pattern is clear once it is laid out: strong consistency in rodents, very little in people. Pepti supplies BPC-157 as a 5 mL vial at 1 mg/mL (5 mg per vial) for $209/mo, all-in, and in several blends listed further down.
BPC-157 Benefits
Benefit by benefit
1. Tendon and ligament repair
What the research describes. This is the most tendon-specific literature of any peptide, and all of it is in rats and rat cells. A 2003 paper in the Journal of Orthopaedic Research reported faster healing of a cut rat Achilles tendon. A 2006 paper in the same journal reported improved reattachment after the Achilles was detached from bone. A 2010 paper, again in the Journal of Orthopaedic Research, cut the medial collateral ligament of the rat knee and reported improved ligament healing over ninety days whether BPC-157 was injected, given in drinking water or applied as a cream. These studies measured things a rat cannot fake: time to weight-bearing, tensile strength and collagen under the microscope.
At the cell level, a 2011 paper in the Journal of Applied Physiology reported increased survival, migration and outgrowth of cultured tendon fibroblasts, with activation of the FAK-paxillin pathway that governs how cells move into a wound. A 2014 paper in Molecules reported increased growth hormone receptor expression in the same cells.
A 2026 paper in Joint Diseases and Related Surgery was the first to test BPC-157 and TB-500 by name in the same tendon experiment, in 32 rats. Load to failure was higher in both peptide groups than in controls, reaching statistical significance for TB-500; BPC-157 alone showed numerically better tissue scores that did not reach significance, and the combination did no better than either alone. The authors call it exploratory.
What it does not show. There is no randomized human trial of BPC-157 for any tendon or ligament injury. Two 2026 reviews in the American Journal of Sports Medicine describe the musculoskeletal evidence as animal-based and call for human trials. The FDA's July 2026 briefing put the ceiling plainly: pharmacological studies suggest BPC-157 "promotes healing of transected tendons in rodents." More on this use is in peptides for tendon and ligament injuries.
2. Protecting the stomach lining
What the research describes. The gut is where BPC-157 research began. The peptide is a fragment of a protein first isolated from human gastric juice, and laboratory work reported it staying intact in gastric juice for hours, which is unusual for a peptide. A 2011 review in Current Pharmaceutical Design summarizes the rodent work: protection of the stomach lining against NSAIDs and alcohol and healing of ulcers along the upper gut. A 2013 paper in the same journal is devoted to NSAID damage in rats.
What it does not show. None of this is human data. No trial has tested whether BPC-157 protects the stomach of a person taking NSAIDs.
3. Inflammatory bowel conditions
What the research describes. A 2013 paper in the Journal of Physiology and Pharmacology reported rats with chemically induced colitis healing more completely with BPC-157. In people, the FDA's 2026 review found one randomized, double-blind, placebo-controlled study: 53 people with mild to moderate ulcerative colitis given a BPC-157 enema or placebo daily for two weeks, reported only as a 2005 meeting abstract. The change in disease activity was larger in the BPC-157 group, but the confidence interval for the difference crossed zero, and because the trial was never published in full, its endpoints and statistics are unknown.
What it does not show. The FDA's reviewers judged that abstract inadequate to support efficacy. BPC-157 is not a treatment for ulcerative colitis or Crohn's disease, and approved treatments for ulcerative colitis exist. Anyone with a diagnosed bowel disease should treat BPC-157 as something discussed alongside a gastroenterologist's care, never instead of it. The wider picture is in peptides for gut health.
4. Fistulas and surgical joins in the bowel
What the research describes. The same 2013 rat paper reported colon anastomoses (surgical joins) healing more completely. A 2016 paper in the European Journal of Pharmacology describes closure of a fistula between bowel and bladder in rats, a 2020 review in Current Pharmaceutical Design gathers the fistula work, and a 2016 paper in PLoS One reports better intestinal adaptation in rats with surgically shortened bowel. The FDA's briefing acknowledged that rat studies reported BPC-157 preventing colonic fistulas and gastrointestinal lesions.
What it does not show. The same briefing noted that dose-response relationships had not been established and the molecular targets had not been identified. There are no human studies of this use.
5. Gut permeability, or "leaky gut"
What the research describes. A 2020 paper in Current Pharmaceutical Design reported, in cell and rat models of NSAID damage, that BPC-157 stabilized intestinal permeability and tight-junction integrity. That single paper is behind most "leaky gut" marketing.
What it does not show. It is a cell and rodent study. "Leaky gut" as a standalone diagnosis is not an established clinical entity, as a 2019 review in Gut sets out, and no human trial has measured permeability on BPC-157.
6. Muscle injury recovery
What the research describes. Animal models of crush injury and of muscle damage caused by local anesthetic report faster functional recovery in the animal. A 2021 paper in Biomedicines extended the work to the myotendinous junction, where muscle meets tendon.
What it does not show. There are no human studies of BPC-157 for muscle injury. It is also not a performance enhancer: nothing in the research describes it adding strength or muscle directly.
7. New blood vessel growth into injured tissue
What the research describes. This is the mechanism behind most of the other claims. A 2017 paper in the Journal of Molecular Medicine reported BPC-157 activating the VEGFR2 receptor and its downstream Akt-eNOS signaling in cells and in a rat model of limb ischemia, and a 2009 paper in the Journal of Physiology and Pharmacology described an effect on blood vessel growth in healing rat muscle and tendon. A 2014 review in Current Pharmaceutical Design summarizes rat work on the nitric oxide system. The logic is that tendons and ligaments have a poor blood supply, and blood supply is often what limits repair.
What it does not show. Nobody has measured this in people. The same mechanism is also the main caution: a tumor needs a blood supply as much as an injured tendon does, which is why cancer history matters (covered below).
8. Knee and joint pain
What the research describes. A 2021 retrospective chart review in Alternative Therapies in Health and Medicine looked at 17 people with knee pain given one or two injections into the joint, some with thymosin beta-4. No adverse events were noted.
What it does not show. A chart review has no control group and no randomization, so it cannot separate an effect from time, placebo or other treatment. It also used injection into the joint, not the under-the-skin route that is prescribed. More context is in peptides for joint health.
9. Liver protection
What the research describes. Animal work describes BPC-157 protecting rat liver from chemical injury, and the FDA's briefing recorded protection against liver lesions in rats.
What it does not show. The signal is mixed. The same FDA review flagged higher ALT (a liver enzyme), glucose and triglycerides in 28-day animal toxicology studies at doses far above anything prescribed. Neither the protective nor the concerning signal has been looked for in people.
10. "Boosting growth hormone"
What the research describes. The 2014 Molecules paper reported more growth hormone receptors on cultured tendon cells, which makes those cells more responsive to growth hormone already present.
What it does not show. It does not raise growth hormone or IGF-1, and no study describes a change in circulating levels. BPC-157 is not a growth hormone secretagogue. Products built for that are CJC-1295 / Ipamorelin and sermorelin.
11. Mood, focus and the brain-gut axis
What the research describes. A 2016 review in Current Neuropharmacology discusses BPC-157 in terms of the brain-gut axis, the two-way signaling between the intestine and the brain.
What it does not show. It is a review of animal work, and this is the part of the literature most often overstated. No human study has measured mood or cognition on BPC-157.
BPC-157 Benefits
The human studies, all of them
The FDA's 2026 literature search found five studies in which BPC-157 was given to people. This is the entire published human experience.
| Year | Design | Route | People | What was reported |
|---|---|---|---|---|
| 2002 to 2003 | Placebo-controlled phase 1, meeting abstracts | Enema | 32 healthy volunteers | Headache and flatulence, no different from placebo |
| 2005 | Randomized, double-blind, placebo-controlled, meeting abstract | Enema, two weeks | 53 with ulcerative colitis | Inconclusive; FDA judged it inadequate for efficacy |
| 2021 | Retrospective chart review | Into the knee joint | 17 with knee pain | No adverse events noted |
| 2024 | Single-arm pilot | Into the bladder wall | 12 women with interstitial cystitis | No adverse events or complications reported |
| 2025 | Pilot | Intravenous, two days | 2 | No adverse events |
Not one of these used the subcutaneous injection that is actually prescribed. The FDA found no human study of subcutaneous BPC-157 and no human data on how much of an injected dose reaches the blood.
BPC-157 Benefits
What the evidence shows, honestly
The rodent literature on BPC-157 is decades deep and internally consistent, and it reports a wide margin between effective doses and doses that cause problems. That is a real case, and it is why the peptide is prescribed. It is not the same as evidence that it works in people, and the honest framing is "described in preclinical research and used clinically," not "proven."
What would change the picture is a randomized human trial with a functional endpoint, in tendinopathy or soft-tissue injury. None had results when the FDA reviewed BPC-157 in July 2026. For tendinopathy specifically, progressive loading under a physical therapist has human trial evidence that BPC-157 does not, so it is reasonable to do that first or alongside. A complete rupture, displaced fracture or significant meniscal tear is a surgical question no peptide changes.
BPC-157 Benefits
Side effects, in summary
BPC-157 is reported as well tolerated in animal work and in clinical use. The full safety picture is in is BPC-157 safe; the short version:
| How often | What is reported | What to do |
|---|---|---|
| Common | Injection-site redness, itching, tenderness, a small firm lump | Rotate sites between abdomen and thigh; mention it at follow-up |
| Common | Mild fatigue or headache in the first week or two | Mention it; it usually settles |
| Uncommon | Nausea or light-headedness shortly after a dose | Report it to your care team |
| Stop and get help | Swelling of the face, lips or throat, widespread rash, difficulty breathing | Emergency care first, then tell your physician |
| Stop and call | A site that is hot, spreading or more painful after 48 hours; any change in skin color; bleeding away from the site | Stop dosing and contact your physician the same day |
The specific cautions are an active or recent cancer (because of the blood vessel mechanism), blood thinners (the FDA flagged clotting-time changes in animal studies), and pregnancy or breastfeeding, where no safety data exists. BPC-157 is named on the 2026 WADA Prohibited List under S0, prohibited at all times, so tested athletes should tell their physician before starting; see is BPC-157 banned.
BPC-157 Benefits
Where BPC-157 stands with the FDA
BPC-157 was placed in Category 2 of the FDA's 503A bulk substances list in 2023. On 15 April 2026 the FDA removed it from Category 2 along with eleven other peptides. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A Bulks List, against the FDA staff's own recommendation; the FDA's final determination is pending. It remains legal to prescribe and to compound by a state-licensed pharmacy. Compounded medications, BPC-157 included, are not FDA approved.
BPC-157 Benefits
How Pepti supplies it
| Product | What is in it | Price |
|---|---|---|
| BPC-157 | 5 mL vial, 1 mg/mL (5 mg BPC-157); also as a pre-filled Pen cartridge with 9 mg | $209/mo |
| BPC-157 + TB-500 | 5 mg BPC-157 and 5 mg TB-500 in 5 mL | $259/mo |
| GLOW | 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 in 5 mL | $259/mo |
| KLOW | 50 mg GHK-Cu, 10 mg KPV, 10 mg BPC-157, 10 mg TB-500 in 5 mL | $259/mo |
| FORTIFY | 5 mg Thymosin A-1, 5 mg BPC-157, 2 mg KPV, 1 mg LL-37 in 5 mL | $289/mo |
| ELEVATE | 5 mg Semax, 5 mg Selank, 10 mg BPC-157, 10 mg KPV in 5 mL | $249/mo |
Each price is all-in: medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. The standard BPC-157 directions are 0.18 mL (18 units) subcutaneously once daily, 27 doses per vial, so a vial lasts about four weeks and refills run every 28 days, one vial per fill. Vials arrive as a multi-dose solution ready to use, with directions printed on the vial, sterile syringes and alcohol prep pads, shipped refrigerated with ice packs. Lot test results are at /quality/lab-results.
How BPC-157 compares with its usual partners is in BPC-157 vs TB-500 and KPV vs BPC-157.
BPC-157 Benefits
Where to get BPC-157 prescribed
BPC-157 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration, and one of the three adverse-event reports in the FDA's database involved exactly such a vial. The prescription route:
- Complete a free online intake covering your history, medications and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your physician stays reachable for questions and dose changes.
Pepti prescribes BPC-157 in all 50 states and DC. Step by step: how to get BPC-157 prescribed online.
References
What this is based on.
References
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts · Molecules (2014) · PMID 25415472
- Krivic A, Anic T, Seiwerth S, et al.. Achilles detachment of rat and stable gastric pentadecapeptide BPC 157 · Journal of Orthopaedic Research (2006) · PMID 16583442
- Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Current Pharmaceutical Design (2011) · PMID 21548867
- Cerovecki T, Bojanic I, Brcic L, Radic B, et al.. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat · J Orthop Res (2010) · PMID 20225319
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, et al.. Stable gastric pentadecapeptide BPC 157-NO-system relation · Curr Pharm Des (2014) · PMID 23755725
- Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H · Drug Test Anal (2017) · PMID 28035768
- Thomas A, Görgens C, Guddat S et al.. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry · J Sep Sci (2016) · PMID 26578461
- Farrar JT, Young JP Jr, LaMoreaux L, Werth JL et al.. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale · Pain (2001) · PMID 11690728
- Meyer JD, Ho B, Manning MC. Effects of conformation on the chemical stability of pharmaceutically relevant polypeptides · Pharm Biotechnol (2002) · PMID 11987755
- Xu C, Sun L, Ren F, Huang P, et al.. Preclinical Safety Evaluation of Body Protective Compound-157, a Potential Drug for Treating Various Wounds · Regul Toxicol Pharmacol (2020) · PMID 32334036
- He L, Feng D, Guo H, et al.. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs · Front Pharmacol (2022) · PMID 36588717
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain · Altern Ther Health Med (2021) · PMID 34324435
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
BPC-157 Benefits, answered.
The benefits described in research are faster tendon and ligament repair, protection of the stomach and intestinal lining, healing of bowel fistulas and surgical joins, muscle recovery and new blood vessel growth into injured tissue. Nearly all of that is from rats and cells. In people there is one inconclusive 2005 enema trial in ulcerative colitis and a few small uncontrolled pilots.
No. There is no randomized human trial of injectable BPC-157 for any use. The only randomized human study used an enema for two weeks in ulcerative colitis, was published only as an abstract, and the FDA judged it inadequate to support efficacy.
Its research is deepest for tendon and ligament repair and for the gut lining, which is why it is most often prescribed for a soft-tissue injury (usually alongside TB-500) or a gut-lining complaint (usually alone). Both rest on animal research.
Rodent studies describe protection of the gut lining against NSAIDs and alcohol, healing of ulcers and fistulas, and stabilized permeability after NSAID damage. Human evidence for gut conditions is limited to one inconclusive enema trial. It is not a substitute for working out what is wrong; see peptides for gut health.
In rats, studies in the Journal of Orthopaedic Research reported faster Achilles tendon healing and better knee ligament healing. No human trial has tested it, so nobody can tell you how much faster a given injury might recover or whether it will at all.
No. Cell research describes more growth hormone receptors on tendon cells, which makes those cells more responsive to growth hormone already present. It does not raise growth hormone or IGF-1 levels.
The only human data is a 2021 retrospective chart review of 17 people given injections into the knee, which noted no adverse events. It had no control group, so it cannot show a benefit.
There is no timeline from human trials, because none have been run. Any timeline you see is prescriber experience, not a measured result. A vial covers about four weeks at the standard directions.
Mostly injection-site redness, itching or a small lump, and sometimes mild fatigue or headache early on. Nausea or light-headedness after a dose is less common. Facial or throat swelling, a widespread rash or difficulty breathing is an emergency.
Anyone with an active or recent cancer, anyone pregnant or breastfeeding, and tested athletes (it is prohibited at all times). People on blood thinners need to tell their physician, because animal studies showed changes in clotting time.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.